On Invalid Date, Akebia Therapeutics (NASDAQ: AKBA) reported Q4 2023 earnings per share (EPS) of $0.00, up 100% year over year. Total Akebia Therapeutics earnings for the quarter were $614.00 thousand. In the same quarter last year, Akebia Therapeutics's earnings per share (EPS) was -$0.04.
As of Q2 2024, Akebia Therapeutics's earnings has grown year over year. Akebia Therapeutics's earnings in the past year totalled -$51.93 million.
What is AKBA's earnings date?
Akebia Therapeutics's earnings date is Invalid Date. Add AKBA to your watchlist to be reminded of AKBA's next earnings announcement.
What was AKBA's revenue last quarter?
On Invalid Date, Akebia Therapeutics (NASDAQ: AKBA) reported Q4 2023 revenue of $56.20 million up 0.74% year over year. In the same quarter last year, Akebia Therapeutics's revenue was $55.78 million.
What was AKBA's revenue growth in the past year?
As of Q2 2024, Akebia Therapeutics's revenue has grown -33.46% year over year. This is 179.19 percentage points lower than the US Biotechnology industry revenue growth rate of 145.73%. Akebia Therapeutics's revenue in the past year totalled $194.62 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.